Loncastuximab Tesirine ‘Could Change Practice’ for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The antibody-drug conjugate demonstrated durable antitumor activity in heavily pretreated patients.
Lymphoma
Oncology Nurses’ Role in Managing Care of Patients With Primary Central Nervous System Lymphoma
This review of PCNSL focuses on the nurse’s role in managing the care of patients with rare disease that has a poor prognosis.
Older Patients With NHL at High Risk for Treatment-Related Toxicity Events
A retrospective study revealed age-based risks for toxicities in patients with NHL treated with high-dose chemotherapy and autologous hematopoietic cell transplantation.
Ofatumumab Plus Bendamustine Does Not Confer a Survival Benefit in Indolent Non-Hodgkin Lymphoma
Progression-free and overall survival outcomes were similar with and without ofatumumab.
HDMTX Promising for Patients With Primary CNS Lymphoma Ineligible for Clinical Trials
Researchers compared outcomes in patients with PCNSL who did not meet clinical trial criteria with those of patients from a major multicenter clinical trial of PCNSL.
Circulating Tumor DNA May Predict Outcomes of CAR T-Cell Therapy in Large B-Cell Lymphoma
Circulating tumor DNA may identify patients at risk of relapse after axicabtagene ciloleucel.
Older Patients With NHL at High Risk for Treatment-Related Toxicity Events
A retrospective study revealed age-based risks for toxicities in patients with NHL treated with high-dose chemotherapy and autologous hematopoietic cell transplantation.
MATRIX Provides ‘Excellent, Long-Lasting Survival’ in Primary CNS Lymphoma
The 7-year survival results were superior with MATRIX.
Tislelizumab Deemed an ‘Important Option’ for Relapsed/Refractory Classical Hodgkin Lymphoma
The median overall survival was not reached at 3 years.
DLBCL: Naratuximab Shows Promise Among Patients With Relapsed/Refractory Disease
The overall response rate was 44.7% after a median follow-up of 15 months.
- Loading...
Loading...
Loading... 
Loading...